drugset / Trial / NCT00216151
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Phase 2
Terminated
3 enrolled
Hoosier Cancer Research Network
Novartis Pharmaceuticals · collabWalther Cancer Institute · collab
RandomizedSingle-groupOpen-labelPrevention
Summary
Evidence for the beneficial effects of bisphosphonates on bone resorption in multiple myeloma has been reported extensively, showing reductions in skeletal events and improvement of several biochemical variables in bone resorption. Zoledronic acid (Zometa®, CGP42446) is the most potent clinically available bisphosphonates, with the largest therapeutic ratio between the desired inhibition of calcium resorption and the unwanted inhibition of mineralization in vitro of all the bisphosphonates. This trial will investigate the efficacy of zoledronic acid in preventing skeletal events in patients with asymptomatic/early stage Multiple Myeloma
Timeline
- Start
- 2005-06
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Zoledronic acid | Other / unclassified | 4 mg | — |